Last10K.com

Anika Therapeutics, Inc. (ANIK) SEC Filing 8-K Material Event for the period ending Friday, November 12, 2021

Anika Therapeutics, Inc.

HISTORY TOOLS
CIK: 898437 Ticker: ANIK

View differences made from one to another to evaluate Anika Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anika Therapeutics, Inc..

Continue

Assess how Anika Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anika Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Cover

Material Contracts, Statements, Certifications & more

Anika Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract
Ticker: ANIK
CIK: 898437
Form Type: 8-K Corporate News
Accession Number: 0001171843-21-007914
Submitted to the SEC: Mon Nov 15 2021 7:58:19 AM EST
Accepted by the SEC: Mon Nov 15 2021
Period: Friday, November 12, 2021
Industry: Surgical And Medical Instruments And Apparatus
Events:
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anik/0001171843-21-007914.htm